Roth Capital Has Bullish Estimate for GANX FY2025 Earnings

Gain Therapeutics, Inc. (NASDAQ:GANX) – Roth Capital upped their FY2025 earnings estimates for shares of Gain Therapeutics in a research note issued on Wednesday, November 12th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will earn ($0.64) per share for the year, up from their prior forecast of ($0.69). Roth Capital currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q4 2025 earnings at ($0.14) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.20) EPS and FY2026 earnings at ($0.62) EPS.

A number of other equities analysts have also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Wednesday, October 8th. BTIG Research restated a “buy” rating and set a $9.00 price objective on shares of Gain Therapeutics in a report on Wednesday, October 15th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a report on Monday, October 13th. Finally, Maxim Group boosted their price target on shares of Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.86.

Gain Therapeutics Trading Down 5.4%

NASDAQ:GANX opened at $2.83 on Monday. The stock has a market cap of $102.56 million, a price-to-earnings ratio of -4.64 and a beta of 0.13. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.52 and a current ratio of 2.52. Gain Therapeutics has a 1 year low of $1.41 and a 1 year high of $3.06. The business has a fifty day moving average of $1.94 and a 200-day moving average of $1.83.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15).

Institutional Investors Weigh In On Gain Therapeutics

A number of institutional investors have recently made changes to their positions in GANX. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Gain Therapeutics in the third quarter valued at about $28,000. JPMorgan Chase & Co. acquired a new position in shares of Gain Therapeutics during the 3rd quarter worth approximately $47,000. Benedict Financial Advisors Inc. increased its holdings in shares of Gain Therapeutics by 55.6% during the third quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock worth $62,000 after purchasing an additional 12,500 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Gain Therapeutics in the third quarter valued at approximately $68,000. Finally, Kovitz Investment Group Partners LLC acquired a new stake in shares of Gain Therapeutics in the first quarter valued at approximately $91,000. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.